Avantor's third quarter delivered the inflection the turnaround story needed. Organic revenue grew 5.2% after three straight quarters of decline. Adjusted EPS of $0.22 beat the $0.21 consensus by 4.8%, and revenue of $1.698 billion topped the $1.64 billion estimate by 3.6%, rising 4.6% year over year. Management raised full-year guidance for a third consecutive quarter. Profits did not follow sales, however. Earnings growth was 0.0% year over year, with adjusted EPS flat at $0.22. That is the central tension: the top line has turned, but the company has not yet shown it can convert growth into higher profit.

The quality of the quarter deserves scrutiny below the revenue line. Adjusted EBITDA margin fell to 15.1% from 16.5% a year ago. Adjusted operating margin slipped to 13.4% from 14.6%, and adjusted net income declined to $146.4 million from $151.1 million. The pressure was concentrated in VWR Distribution & Services. Its organic growth accelerated to 5.8%, but adjusted operating income dropped to $119.4 million from $132.0 million, and margin compressed to 9.7% from 11.2%. The company blamed unfavorable mix and higher SG&A. GAAP results also need context. Diluted EPS of $0.30 was lifted by a $105.4 million income tax benefit, and the swing from last year's $711.8 million loss mostly reflects the absence of the prior year's $785 million goodwill impairment. Free cash flow of $156.2 million was solid but trailed the prior year's $171.7 million.

The call showed how sharply the revenue trajectory has changed. Organic growth moved from roughly -4% in the first quarter to -0.4% in the second and +5.2% in the third, well above the roughly 2.5% the second-quarter outlook had implied. VWR's path ran from -5% to +1.7% to +5.8%, and management attributed about half of the gain to commercial initiatives rather than market lift. Bioscience & Medtech Products swung from -5.6% to +3.6%. NuSil grew in the low teens, process chemicals rose high single digits, and book-to-bill was positive for a third straight quarter. Demand broadened beyond pharma and biotech into North American academia and early-stage biotech, and management described the environment as the most constructive in several years. Sequentially, margins are improving modestly: adjusted EBITDA margin went from 13.9% to 15.0% to 15.1%, and BMP's margin rose to 26.6% from 26.0% in the second quarter, though it was flat year over year.

The guidance raise is real but uneven. Full-year organic growth moved to +0.75% to +1.25%, up from -0.5% to +0.5%. Free cash flow guidance narrowed upward to $525 million to $550 million. Adjusted EPS guidance rose only at the low end, to $0.81 to $0.83, and the 14.8% to 15.3% EBITDA margin range was left unchanged. That combination reinforces the margin problem. The implied fourth-quarter organic growth of 2.5% to 4.5% is a deceleration. BMP faces a roughly 400-basis-point electronic materials headwind and a tougher process chemicals comparison, and it is guided only flat to slightly positive. Middle East-related inflation, lower-margin mix within VWR, and a lagging European recovery give bears legitimate ammunition. Management deferred the VWR path to a 12% to 13% margin and any 2027 detail to the December 8 Investor Day and the February call.

Other developments support the story:

• A new CFO and CIO complete the leadership team.
• The NuSil contract with a key customer was renewed through 2031.
• Adjusted net leverage fell to 3.1x, and management expects it below 3.0x by year-end.

The market moved ahead of the print. Shares opened at $14.49 after the July report and stood at $17.13 heading into this release, a gain of 18.2%. That left the stock just 1.8% below its $17.45 inter-earnings and 52-week high, set on October 22, and nearly 54% above its 200-day moving average. Investor sentiment improved substantially, from -0.31 to -0.03, but remained slightly negative. Investors are no longer betting against the turnaround, yet they have not fully embraced it. Earnings Whispers trend readings are mostly positive, with price, momentum and AVWAP constructive, while sequential growth is neutral.

The bottom line is that Avantor answered the most pressing question, whether revenue could grow again, more decisively than expected. With shares already near their highs, the next test is profitability. The company needs to show that growth will lift margins and EPS rather than simply offset mix and inflation pressure. A decelerating fourth-quarter outlook and an unchanged margin guide leave that question open until Investor Day.